K-lactic acid bacteria colon cancer treatment innovation 'DUOLAC' announced that it participated in 'Vitafoods Europe 2025' held in Barcelona, Spain from May 20th to 22nd (local time). In this exhibition, Cell Biotech DUOLAC participated with an independent booth to promote the excellence of K-lactic acid bacteria and explored various business opportunities with the goal of expanding exports to the European market.
'Vitafood Europe' is the world's largest health functional food fair that started in 1997, and is an important event where you can see global trends and technological developments at a glance. This year's fair was attended by 1,400 companies from 162 countries, and over 20,000 industry experts gathered to share the latest trends in the health functional food industry.
Cell Biotech introduced two new products, 'DUOLAC Brain Guard' and 'DUOLAC Slim Pet', in the 'New Product Zone' and 'Pet Nutrition Zone', which introduce the most innovative products.
In addition, Cell Biotech emphasized its global competitiveness by introducing its lactic acid bacteria development technology and manufacturing know-how, such as the commencement of clinical trials for the innovative new colorectal cancer drug 'PP-P8' utilizing K-lactic acid bacteria, obtaining the world's largest number of US FDA GRAS listings, and additionally obtaining 'OK Kosher' certification.
A representative of Cell Biotech said, “The Vitafoods Europe Expo is a very important event where Duolac, the representative Korean probiotic brand, can demonstrate the technological prowess and strength of K-probiotics in the global market,” adding, “We will continue to secure an edge in competition with major global companies through continuous research and development and strengthening of our technological prowess, and expand new export bridgeheads.”
- See more related articles
You must be logged in to post a comment.